Norwegian-Estonian Research Cooperation

Kåre Birkeland's Research Group for Type 2 diabetes and Metabolism at Oslo Diabetes Research Centre has entered into a collaborative research project with the Estonian company IPDx funded by the Green ICT programme (Norway-Estonia) with an implementation period of 01.09.2020 – 30.06.2022.

IPDx is an Estonian company that have developed a novel and exciting immunoprofiling method that maps the billions of antibodies to their antigens. The aim of the project is to enhance IPDx immunoprofiling methodology, while also elucidating the immune response in diabetic patients, to understand more about early development of type 2 diabetes and to further develop promising biomarker candidates for the early detection of diabetes.